Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025

Presentations at the Congress will feature new or updated findings from Merck's broad portfolio of cancer medicines, including data for KEYTRUDA (pembrolizumab); LENVIMA (lenvatinib), in collaboration with Eisai; WELIREG (belzutifan); and KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa- pmph). Key data being presented on existing medicines in Merck's portfolio: Additionally, new data for investigational antibody-drug conjugates (ADCs) from Merck's innovative pipeline will be presented at the Cong ...